FIG 1.

Experimental design. Ten Mamu-B*08⁺ RMs were vaccinated with an rAd5/rVSV/rRRV regimen expressing the immunodominant Mamu-B*08-restricted epitopes Vif RL8, Vif RL9, and Nef RL10. Six Mamu-B*08⁺ RMs were sham vaccinated and served as the controls. At week 41, vaccine efficacy was assessed by subjecting all monkeys to repeated IR challenges with a marginal dose of SIVmac239 (200 TCID₅₀) every 2 weeks. The results for four vaccinees are color coded in blue in this figure and subsequent ones because they resisted greater than six IR challenges with SIVmac239.